IV Medications Elsevier
45
Quality Score
Emerging
IV Medications Elsevier
Low confidence
✍️ bumetric analysis
“
IV Medications Elsevier is an Android app from Skyscape Medpresso Inc in the Medical category, currently rated 3.7★ across 44 ratings. Initial signal reads as mixed reviews: supporters praise core features while critics cite stability and value gaps.
Quality Score is 45: Emerging (early traction worth watching). For a Medical app, that means early traction worth watching. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
💰 Monthly revenue · now vs forecast
● Right now
$5.0K
per month
→
12-mo forecast
$5.2K – $10.8K
per month
→
24-mo forecast
$6.4K – $19.2K
per month
MID tier
💡 Grow this revenue
Free AI audit of this app’s store listing
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
Typical impact: +2-5× organic installs
📊 Performance Tracking LIVE
Loading…
Rating
—
Reviews
—
Forecast Revenue / mo
—
Snapshots tracked
0
since first record
ONE-TIME · BUILD
💰 Estimated build cost
$145K
↳ What it cost to build · not monthly revenue
Likely range $110K – $195K
$25K · MVP floor
$100K · indie scale
$500K+ · studio build
📈
Slow ROI — current MRR is well below build cost
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
Where the money goes
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| 💎 In-app purchase plumbing | +$9K |
| ⚙ Medical complexity ×1.55 | +$32K |
| 🌐 Cross-platform reach (iOS + Android) | +$50K |
Total estimate
$145K
🔬
How we forecast this revenue
MEDIUM CONFIDENCEBaseline
$5.0K/mo · ML-estimated from 234 triggers
Growth rate
+4.0% MoM · MID tier baseline (compound monthly)
Direction
Headwinds: rating drift may slow acquisition
6 months
$4.7K – $7.9K
12 months
$5.2K – $10.8K
24 months
$6.4K – $19.2K
Compound growth at +4.0% MoM (tier baseline for MID). Range widens with horizon — typical noise band ±25% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊
BU Investment Matrix
Below median · 53/100MID TIERunderperforming peersRevenue Strength
3.7
Product Quality
2.9
Market Position
0.0
Growth Velocity
5.0
Defensibility
9.8
Operational Safety
10.0
Founder Strength
7.2
Monetization Maturity
4.0
- 💰 Revenue: Modest — $3K - $7K/mo · MID tier · medium confidence, trajectory unclear.
- ⭐ Quality: 3.67★ across 44 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: Insufficient signal to assess trajectory.
- ⚠️ Risk: Low — no material risk signals detected.
🎯 For competitors: Mixed picture. Worth competing if you have a clear UX or pricing edge — otherwise crowded segment.
💵 For acquirers: Estimated asking range 18-32× monthly = $90K-$160K. Portfolio play ($47K/mo combined) commands premium.
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:
💰 Forecast Revenue / mo
MODELRevenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
🔬Forecast Breakdown — Why This Estimate?Top 3 of 3 triggers
Our ML model uses 200+ signals from public data. These are the most influential for this app:
| Mature app (8y old)METRIC | +$1,500 | |
| Ad-supported / freemiumMETRIC | +$600 | |
| Pre-traction phase (44 ratings)METRIC | −$300 |
METRIC = structural app data · REVIEW = mined from user reviews · ✓ VERIFIED = Stripe-verified anchor (TrustMRR)
📈 Reviews Growth
LIVECumulative review count from first BU snapshot. Each point = a tracked update.
⭐ Rating Trend
LIVEAverage rating evolution. Updates with each new review batch.
Profile & Insights
Everything we know — and don't — about this app and its company.
Identification
- App name
- IV Medications Elsevier
- Developer
- Skyscape Medpresso Inc
- Bundle ID
- com.medpresso.Lonestar.ivmed
- App Store URL
- Open in App Store
- Category
- Medical
- Content rating
- Not found
- Languages
- Not found
Company
- Website
- www.skyscape.com
- Tagline
- Not found
- Description
- Not found
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $116/mo
- Top-grossing rank
- Not found
- All-time revenue
- Not found
- Pricing
- $25.99 - $49.99 per item
Founder
Founder data not yet collected for this app.
Funding
Funding data not yet collected for this app.
Press & Links
Press & Links data not yet collected for this app.
Contacts & Socials
Contacts & Socials data not yet collected for this app.
📈Ratings growth44 ratings+42% lifetimeShow 3-year history estimate ▾
Tracked (1 weeks) Pre-tracking estimate (37 weeks) · model-based, ±5% noise · anchored to release date and current value
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.
📝 About this app
"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.
For nearly 50 years - #1 IV drug handbook to safely administer more than 400 intravenous drugs! Drug monographs for 10-20 newly approved drugs by the FDA include the most current information
Elsevier’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format.… View full description on the official store →
For nearly 50 years - #1 IV drug handbook to safely administer more than 400 intravenous drugs! Drug monographs for 10-20 newly approved drugs by the FDA include the most current information
Elsevier’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format.… View full description on the official store →
App Specs
🔐 Own this app? Claim & verify MRR →🔖 v3.13.1🔄 updated 0d ago📂 Medical💰 Free💎 IAP $25.99 - $49.99 per item
🧪
Tech & Domain Intel — skyscape.com
- Mail provider
- Microsoft 365
- Tech stack
- Google Workspace
Derived from public RDAP + DNS TXT records (no scraping, no login).
🔔
Track this app’s revenue
FREEGet an email when revenue moves by your threshold. No spam, unsubscribe in one click.
📝 Description
95
BU Score · Transcendent
More by Skyscape Medpresso Inc
View all →📦 Portfolio summaryINDIE studio
135apps·$47K/mocombined
✓ Diversified — top app contributes 36%; risk spread across portfolio
About this analysis
Why low confidence: only 44 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
❓ Frequently Asked Questions
4 answers · auto-generated from this app's public dataHow much does IV Medications Elsevier make per month?▴
Based on our ML-calibrated revenue forecast, IV Medications Elsevier earns approximately $115/mo. This is a US-storefront-equivalent estimate; global revenue can be several times larger for internationally-distributed apps. See the methodology page for the full formula and confidence bands.
What apps are like IV Medications Elsevier?▴
Browse the full Medical category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
Who makes IV Medications Elsevier?▴
IV Medications Elsevier is published by Skyscape Medpresso Inc on the Google Play Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.
What is IV Medications Elsevier's BU Score?▴
IV Medications Elsevier has a BU Score of 45/100 (Emerging). The score combines App Store rating, ratings count, monetization model and revenue signals calibrated against founder-verified MRR anchors. See the BU Score formula.